{
  "emaEpar": [],
  "fdaDrugLabel": [],
  "id": "Talabostat",
  "nciThesaurus": {
    "casRegistry": "149682-77-9",
    "chebiId": "",
    "chemicalFormula": "C9H19BN2O3",
    "definition": "A small molecule with antineoplastic and hematopoiesis- stimulating activities. By cleaving N-terminal Xaa-Pro or Xaa-Ala residues, talabostat inhibits dipeptidyl peptidases, such as fibroblast activation protein (FAP), resulting in the stimulation of cytokine and chemokine production and specific T-cell immunity and T-cell dependent activity. This agent may also stimulate the production of colony stimulating factors, such as granulocyte colony stimulating factor (G-CSF), resulting in the stimulation of hematopoiesis. Dipeptidyl peptidases are involved in the activation of polypeptide hormones and chemokines.",
    "fdaUniiCode": "KZ1O2SH88Z",
    "identifier": "C48264",
    "preferredName": "Talabostat",
    "semanticType": "Pharmacologic Substance",
    "subclassOf": [
      "C783"
    ],
    "synonyms": [
      "BXCL 701",
      "BXCL-701",
      "BXCL701",
      "PT-100",
      "TALABOSTAT",
      "Talabostat",
      "[(2R)-1-[(2S)-2-amino-3-methylbutanoyl]pyrrolidin-2-yl]boronic acid",
      "talabostat"
    ]
  }
}